Epizyme Feb 2009 - Oct 2018
Principal Scientist, Translational Medicine
Merck Feb 2007 - Feb 2009
Research Biologist
Bayer Healthcare 2000 - 2007
Senior Associate Scientist
Agios Pharmaceuticals 2000 - 2007
Director, Translational Medicine
Education:
University of New Haven 1999 - 2001
Master of Science, Masters, Molecular Biology
Plymouth State University 1995 - 1999
Bachelors, Bachelor of Science, Biology
Dr. Daigle graduated from the Louisiana State University School of Medicine at Shreveport in 1990. He works in Seattle, WA and specializes in Family Medicine. Dr. Daigle is affiliated with VA Puget Sound Healthcare Seattle Division.
Edward James Olhava - Newton MA, US Richard Chesworth - Boston MA, US Kevin Wayne Kuntz - Woburn MA, US Victoria M. Richon - Wellesley MA, US Roy Macfarlane Pollock - Medford MA, US Scott Richard Daigle - Newburyport MA, US
Assignee:
Epizyme, Inc. - Cambridge MA
International Classification:
A61K 31/70 C07H 19/00
US Classification:
514 46, 536 276
Abstract:
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Richard Chesworth - Concord MA, US Kevin W. Kuntz - Woburn MA, US Victoria M. Richon - Wellesley MA, US Roy M. Pollock - Medford MA, US Scott R. Daigle - Newburyport MA, US
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Scott Richard DAIGLE - Newburyport MA, US
International Classification:
A61K 31/5377 C12Q 1/6886
Abstract:
The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations in one or more sequences encoding a gene listed in Tables 1-9, Tables 17-19, and/or FIGS. -
- Cambridge MA, US Richard CHESWORTH - Concord MA, US Kevin W. KUNTZ - Woburn MA, US Victoria M. RICHON - Wellesley MA, US Roy M. POLLOCK - Medford MA, US Scott Richard DAIGLE - Newburyport MA, US
International Classification:
A61K 31/7076 A61K 31/52
Abstract:
The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Richard CHESWORTH - Concord MA, US Kevin W. KUNTZ - Woburn MA, US Victoria M. RICHON - Wellesley MA, US Roy M. POLLOCK - Medford MA, US Scott R. DAIGLE - Newburyport MA, US
The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US Scott Richard DAIGLE - Newburyport MA, US
International Classification:
A61K 31/5377 C12Q 1/6886
Abstract:
The disclosure provides a method of treating cancer in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method, the subject has one or more mutations in one or more sequences encoding a gene listed in Tables 1-9, Tables 17-19, and/or FIGS. -
Dot1L Inhibitors For Use In The Treatment Of Leukemia
- Cambridge MA, US Scott R. Daigle - Newburyport MA, US
International Classification:
A61K 31/7076 C12Q 1/6886 A61K 31/7064
Abstract:
The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
- Cambridge MA, US - Summit NJ, US Scott Richard DAIGLE - Newburyport MA, US Roy MacFarlane POLLOCK - Medford MA, US Vivek CHOPRA - San Francisco CA, US
The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
de-escalation techniques to handle situations that get out of control in emergency rooms. A revised version of the bill would make allowances for people with mental illness, dementia or developmental disabilities be exempt from enhanced penalties, said Howards chief of staff, Scott Daigle. SB 36